Skip to main content

Drug Interactions between selexipag and trofinetide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

selexipag trofinetide

Applies to: selexipag and trofinetide

MONITOR: Coadministration with trofinetide may increase the plasma concentrations of drugs that are substrates of organic anion transporting polypeptide 1B1 (OATP1B1) and/or 1B3 (OATP1B3) via inhibition of these transporters. Clinical and pharmacokinetic data are currently lacking.

MANAGEMENT: Caution is advised if trofinetide is used concomitantly with substrates of OATP1B1 or OATP1B3, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for trofinetide recommends avoiding coadministration with OATP1B1/3 substrates for which minimal concentration changes may lead to serious toxicities. If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever trofinetide is added to or withdrawn from therapy. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.

References (1)
  1. (2023) "Product Information. Daybue (trofinetide)." Acadia Pharmaceuticals

Drug and food interactions

Minor

selexipag food

Applies to: selexipag

Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower. Selexipag systemic exposure (AUC) and that of its active metabolite did not significantly change, however. Selexipag may be taken with or without food. Tolerability may be improved when taken with food.

References (1)
  1. (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer